Skip to search formSkip to main contentSkip to account menu

ranolazine

Known as: Renolazine, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-, Ranolazine [Chemical/Ingredient] 
An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti… 
National Institutes of Health

Related topics

Related topics

17 relations
12 HR ranolazine 500 MG Extended Release Oral Tablet [Ranexa]Angina PectorisAntianginalsIn Blood

Broader (2)

Cardiovascular AgentsSodium Channel Blockers

Narrower (3)

RS 43285RS 43285-193Ranexa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived…
2010
2010
Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability
BackgroundA direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link between SCN9A… 
Highly Cited
2008
Highly Cited
2008
State- and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by Ranolazine
Ranolazine is an antianginal agent that targets a number of ion channels in the heart, including cardiac voltage-gated Na… 
2008
2008
Ranolazine Inhibits An Oxidative Stress-induced Increase in Myocyte Sodium and Calcium Loading During Simulated-demand Ischemia
Ranolazine inhibits the late Na+ current and is proposed to reduce angina by decreasing [Na+]i during ischemia, thereby reducing… 
2008
2008
Antitorsadogenic Effects of (±)-N-(2,6-Dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (Ranolazine) in Anesthetized Rabbits
Ranolazine [Ranexa; (±)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine] is novel anti-ischemic… 
Review
2007
Review
2007
Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment.
Highly Cited
2007
Highly Cited
2007
A Comparison between Ranolazine and CVT-4325, a Novel Inhibitor of Fatty Acid Oxidation, on Cardiac Metabolism and Left Ventricular Function in Rat Isolated Perfused Heart during Ischemia and…
Inhibition of fatty acid oxidation has been reported to be cardioprotective against myocardial ischemic injury; however, recent… 
Review
2007
Review
2007
Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Chronic Angina resistant to medical treatment with hemodynamically acting agents is a major problem in clinical setup. For such… 
2005
2005
Effect of Hepatic Impairment on the Multiple‐Dose Pharmacokinetics of Ranolazine Sustained‐Release Tablets
The effect of hepatic impairment on the pharmacokinetics of a sustained‐release formulation of ranolazine and 3 major metabolites… 
Highly Cited
2001
Highly Cited
2001
Evidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system
Abstract. The clinical anti-anginal effectiveness of ranolazine is currently being evaluated. However, the mechanism of its anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)